Want to see CBUS full AI Analyst Report?
CBUS Stock Chart & Stats
$1.59
-$0.23(-7.99%)
At close: 4:00 PM EST
$1.59
-$0.23(-7.99%)
Day’s Range― - ―
52-Week Range$1.09 - $4.19
Previous CloseN/A
Volume64.89K
Average Volume (3M)154.04K
Market Cap
$106.10M
Enterprise Value$304.50M
Total Cash (Recent Filing)$30.32M
Total Debt (Recent Filing)$276.15M
Price to Earnings (P/E)―
Beta2.76
Next Earnings
Aug 06, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding76,331,635
10 Day Avg. Volume164,630
30 Day Avg. Volume154,044
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)36.47
Price to Sales (P/S)218.79
P/FCF Ratio-15.56
Enterprise Value/Market Cap2.87
Enterprise Value/Revenue71.05
Enterprise Value/Gross Profit98.58
Enterprise Value/Ebitda-4.89
Forecast
1Y Price Target
$25.00Price Target Upside1472.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.22
Revenue Forecast (FY)$7.79M
Bulls Say, Bears Say
Bulls Say
Platform & Regulatory MomentumSustained platform improvements and regulatory clarity materially raise the odds of scalable trait commercialization. Higher editing efficiency and new regeneration capabilities increase throughput and pipeline scope, while multiple positive USDA determinations reduce regulatory risk across future product launches.
LATAM Rice & Biofragrance Commercial PathsConcrete LATAM commercialization plans plus early sustainable‑ingredients orders create real pathways to recurring royalties. Geographic phasing and initial customer payments indicate pragmatic go‑to‑market execution and diversified potential revenue streams beyond a single crop or market.
Expense Reductions & Capital Raise Extend RunwayMaterial cost discipline plus recent financings have meaningfully extended the company’s ability to execute. Lower R&D and SG&A reduce near‑term dilution risk and provide time for commercialization milestones to mature, improving survival odds while commercialization scales.
Bears Say
Heavy Cash Burn & Limited RunwayPersistent, large negative operating cash flow relative to a small revenue base creates structural financing risk. Even with recent raises, the company must materially convert programs to revenue or secure additional capital before runway ends, which can dilute shareholders or constrain operations.
Commercial Agreements Still Early‑StageDependence on nonbinding LOIs and partner execution leaves projected royalties uncertain. Commercial launches hinge on partners’ definitive commitments, regulatory approvals, and external inputs (chemistry, seed adoption), making revenue realization execution‑dependent over the medium term.
Structural Profitability Weakness & Royalty InterestVery large operating losses relative to revenue and growing non‑operating interest on royalty liabilities indicate weak earnings quality. Until royalties scale, interest expenses and negative margins will pressure cash flow and limit reinvestment capacity, impeding sustained profitability.
Cibus News
CBUS FAQ
What was Cibus’s price range in the past 12 months?
Cibus lowest stock price was $1.09 and its highest was $4.19 in the past 12 months.
What is Cibus’s market cap?
Cibus’s market cap is $106.10M.
When is Cibus’s upcoming earnings report date?
Cibus’s upcoming earnings report date is Aug 06, 2026 which is in 34 days.
How were Cibus’s earnings last quarter?
Cibus released its earnings results on May 14, 2026. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.27 by -$0.06.
Is Cibus overvalued?
According to Wall Street analysts Cibus’s price is currently Undervalued.
Does Cibus pay dividends?
Cibus does not currently pay dividends.
What is Cibus’s EPS estimate?
Cibus’s EPS estimate is -0.27.
How many shares outstanding does Cibus have?
Cibus has 76,331,635 shares outstanding.
What happened to Cibus’s price movement after its last earnings report?
Cibus reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.27. Following the earnings report the stock price went down -7.092%.
Which hedge fund is a major shareholder of Cibus?
Currently, no hedge funds are holding shares in CBUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cibus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (1472.33% Upside)
$25.00 (1472.33% Upside)
Hedge Fund Trend
Decreased
By 22.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.92%
12-Months-Change
Fundamentals
Return on Equity
-225.59%
Trailing 12-Months
Asset Growth
-3.24%
Trailing 12-Months
Company Description
Cibus
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
CBUS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized execution: material commercial progress in LATAM rice (LOI, import permit, delivery of edited materials), clear technical advances (order-of-magnitude improvement in editing efficiency; wheat single-cell regeneration), regulatory tailwinds, and tangible cost reductions that materially improved the P&L and extended runway after raising ~ $37M gross. Offsets include a limited cash runway into Q1 2027 absent stronger near-term revenue, a U.S. rice launch delay from 2028 to 2029 due to herbicide registration timing, continued sizable quarterly net losses and interest on royalty liabilities, and several commercial arrangements still at LOI or early stages. Overall, the positives (capital raise, execution on priority programs, technical and regulatory momentum, and meaningful expense reductions) outweigh the negatives, though the company's trajectory remains execution-dependent.View all CBUS earnings summariesCBUS Stock 12 Month Forecast
Average Price Target
$25.00
▲(1472.33% Upside)
Technical Analysis
Ownership Overview
25.66% Insiders
9.60% Mutual Funds
5.25% Other Institutional Investors
56.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---